A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Twenty-five percent inhaled nitrous oxide improves symptoms of treatment-resistant major depression with fewer adverse effects than the 50% concentration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a Phase 2 trial of 25 and 50% inhaled nitrous oxide for TRD (n = 24) found significant improvement in depressive symptoms in both nitrous oxide groups”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [180]
In the citing paper
“with a significantly lower rate of adverse events in the 25% nitrous oxide group [180]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [180]
In the citing paper
“The antidepressant effects of N2O are mediated through antagonism of the metabotropic glutamatergic NMDA receptors (121).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [121]
In the citing paper
“Nagele and colleagues found that inhaled N2O at a concentration of either 25% or 50% significantly reduced scores on the Hamilton Depression Rating Scale (HDRS) at week 2 in patients with treatment resistant depression.”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [121]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
(2018) · The SAGE Encyclopedia of Educational Research, Measurement, and Evaluation · doi:10.4135/9781506326139.n404 · Cited by 1,528
Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin
Jevtović-Todorović, V., Todorovć, S. M., Mennerick, S., Powell, S., Dikranian, K., Benshoff, N., Zorumski, C. F., & Olney, J. W. (1998) · Nature Medicine · doi:10.1038/nm0498-460 · Cited by 676
Self-citationA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
Gibbons, R. D., Brown, C. H., Hur, K., Davis, J. M., & Mann, J. J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2048 · Cited by 291
Self-citationGibbons, R. D., Hur, K., Brown, C. H., Davis, J. M., & Mann, J. J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2044 · Cited by 271
Self-citationDunner, D. L., Rush, A. J., Russell, J. M., Burke, M., Woodard, S., Wingard, P., & Allen, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0501 · Cited by 234 · cited 1×
“INTRODUCTION Treatment-resistant major depression (TRMD) is a severe form of major depressive disorder (MDD) in which patients fail to respond to multiple standard antidepressant treatments (1, 2).”
BackgroundNitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., Janski, A., Panagopoulos, V. N., Cristancho, P., Miller, J. P., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.016 · Cited by 230 · cited 2×
“A proof-of-principle study demonstrated that a 1-hour inhalation of 50% nitrous oxide (“laughing gas”) has rapid antidepressant effects in patients with TRMD (7).”
BackgroundSelf-citationEffect of Nitrous Oxide on Excitatory and Inhibitory Synaptic Transmission in Hippocampal Cultures
Mennerick, S., Jevtovic-Todorovic, V., Todorovic, S. M., Shen, W., Olney, J. W., & Zorumski, C. F. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09716.1998 · Cited by 224
Self-citationPrevalence of treatment-resistant depression in primary care: cross-sectional data
Thomas, L., Kessler, D., Campbell, J., Morrison, J., Peters, T. J., Williams, C., Lewis, G., & Wiles, N. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x675430 · Cited by 175
Bühre, W., Disma, N. M., Hendrickx, J. F. A., Hert, S. G. D., Hollmann, M. W., Huhn, R., Jakobsson, J., Nägele, P., Peyton, P. J., & Vutskits, L. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.01.023 · Cited by 139
Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents
Kalmoe, M. C., Janski, A. M., Zorumski, C. F., Nagele, P., Palanca, B. J., & Conway, C. R. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116778 · Cited by 74
Self-citationNagele, P., Metz, L. B., & Crowder, C. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402825101 · Cited by 69
Rush, A. J., Wisniewski, S. R., Zisook, S., Fava, M., Sung, S. C., Haley, C. L., Chan, H. N., Gilmer, W. S., Warden, D., Nierenberg, A. A., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711002170 · Cited by 65
Zorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
Self-citationUse of benzodiazepines, depressive symptoms and cognitive function in old age
van Vliet, P., van der Mast, R. C., van den Broek, M., Westendorp, R. G. J., & de Craen, A. J. M. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2143 · Cited by 51
Das, R. K., Tamman, A., Nikolova, V., Freeman, T. P., Bisby, J. A., Lazzarino, A. I., & Kamboj, S. K. (2016) · Psychological Medicine · doi:10.1017/s003329171600026x · Cited by 49
Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts
Nagele, P., Zorumski, C. F., & Conway, C. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000837 · Cited by 43
Self-citationIs conflict adaptation an illusion?
Schmidt, J. R., Notebaert, W., & den Bussche, E. V. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00172 · Cited by 31
Does Nitrous Oxide Help Veterans With Posttraumatic Stress Disorder? A Case Series
Varias, A., van Roessel, P., Parsiani, M., Filippou-Frye, M., Neylan, T. C., Nagele, P., Yesavage, J., Clark, J. D., & Rodriguez, C. I. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20l13393 · Cited by 20 · cited 1×
“veterans (18) and in an experimental model of psychological trauma to simulate posttraumatic stress disorder (19).”
BackgroundRoch, M., Pesciarelli, F., & Leo, I. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.00692 · Cited by 18
Hong, H. Y., Karadaghy, O. A., Kallogjeri, D., Brown, F. T., Yee, B. E., Piccirillo, J. F., & Nägele, P. (2018) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2018.1278 · Cited by 13
Self-citationProlonged Remission of Major Depressive Disorder After Single Nitrous Oxide Inhalation Treatment
Nägele, P., Brown, F., Bass, V., & Yohanna, D. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00692 · Cited by 10
Self-citation
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“The antidepressant effects of N2O are mediated through antagonism of the metabotropic glutamatergic NMDA receptors (121).”
BackgroundNew and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 179
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 114
Correll, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., Kraemer, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 109
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Metadata
- Authors
- Nagele, P., Palanca, B. J., Gott, B., Brown, F., Barnes, L., Nguyen, T., Xiong, W., Salloum, N. C., Espejo, G. D., Lessov-Schlaggar, C. N., Jain, N., Cheng, W. W. L., Komen, H., Yee, B., Bolzenius, J. D., Janski, A., Gibbons, R., Zorumski, C. F., & Conway, C. R.
- Affiliations
- Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL 60637, USA.
- Washington University in St. Louis (US)
- University of Chicago (US)
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2021-06-09
- Volume
- 13
- Issue
- 597
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3170628472
- Cited by
- 133
- References
- 29
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 26 · 2023: 52 · 2022: 15 · 2021: 5
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Brain and Behavior Research Foundation (24593)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- major depressive disorder, treatment-resistant depression, adverse effects, depression treatment
- MeSH terms
- Antidepressive Agents, Depression, Major Depressive Disorder, Double-Blind Method, Humans, Nitrous Oxide, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.